Epidermal growth factor family of receptor tyrosine kinases (ERBB) family cell surface receptors, including epidermal growth factor receptor (EGFR/ERBB1), are phosphorylated upon binding by various EGF family ligands and signal via multiple kinase pathways. EGFR signaling is enhanced because of mutational activation of EGFR in almost half of glioblastomas, the most common malignant primary brain tumor. Therapeutic targeting of EGFR in glioblastoma has remained largely unsuccessful. Here, we profiled nine longterm (LTC) and five glioma-initiating (GIC) cell lines for expression and activation of ERBB family receptors and expression of their ligands. Receptors and ligands were abundantly expressed, with patterns overall similar to glioblastoma expression profiles in vivo as deposited in The Cancer Genome Atlas database. No differences between LTC and GIC emerged. Irrespective of ligand or receptor expression, neither an EGFR antibody, erbitux, nor an EGFR tyrosine kinase inhibitor, gefitinib, were particularly active against LTC or GIC at clinically relevant concentrations. Selfrenewal capacity of GIC was severely compromised by epidermal growth factor (EGF) withdrawal, but rescued by transforming growth factor alpha (TGF-a), although not by neuregulin-1 (NRG-1). Subcellular fractionation indicated high levels of nuclear phosphorylated EGFR in all LTC and GIC. In LN-229 cells, pERBB2 and pERBB3 were also detected in the nucleus. Nuclear pERBB2 was less sensitive, whereas pERBB3 was induced, in response to gefitinib. This study provides an extensive characterization of human glioma cell models, including stem-like models, with regard to ERBB receptor/ligand expression and signaling. Redundant signaling involving multiple ERBB family ligands and receptors may contribute to the challenges of developing more effective EGFR-targeted therapies for glioblastoma.
ERBB protein family consists of four members, ERBB1, ERBB2, ERBB3 and ERBB4, which are activated upon ligand binding to the extracellular ligand binding domain, triggering receptor homo-or heterodimerization and phosphorylation of certain cytoplasmic tyrosine residues (Yarden and Sliwkowski 2001; Hynes and Lane 2005) . Tyrosine autophosphorylation leads to the recruitment and activation of multiple targets and pathways, for example, the mitogenactivated protein kinase, the phosphatidylinositol 3-kinase/ protein kinase B and the Janus kinase/signal transducer and activator of transcription pathways (Olayioye et al. 2000; Hynes et al. 2001; Yarden and Sliwkowski 2001) .
ERBB family proteins are activated by a group of related ligands: epidermal growth factor (EGF), transforming growth factor alpha (TGF-a) and amphiregulin (AREG) bind specifically to epidermal growth factor (EGF) receptor (EGFR/ ERBB1), whereas heparin-binding epidermal growth factor (HB-EGF), betacellulin (BTC) and epiregulin (EREG) bind to ERBB1 and ERBB4. The neuregulins (NRG1, 2, 3, 4) bind either to ERBB3 and ERBB4 (NRG1,2) or to ERBB4 specifically (NRG3,4). Since none of the ligands can bind to ERBB2 alone and since ERBB3 has weak autophosphorylation properties, both receptors function mainly through heterodimerization with other ERBB receptors, preferentially with each other (Graus-Porta et al. 1997; Hynes et al. 2001; Yarden and Sliwkowski 2001; Shi et al. 2010; Steinkamp et al. 2014) . EGFR is the most frequently amplified gene in glioblastoma (40%), resulting in increased EGFR mRNA and protein levels, and exhibits mutation, rearrangement, deletions and altered splicing, leading to the expression of different aberrant transcript variants (Cancer Genome Atlas Research, 2008 , Brennan et al. 2013 . EGFR gene amplification is common in the classic or receptor tyrosine kinase type 2 molecular subtype of isocitrate dehydrogenase-wildtype glioblastoma (Sturm et al. 2012; Brennan et al. 2013) . Half of EGFR-amplified glioblastomas carry a tumor-specific deletion variant (EGFRvIII) characterized by an in-frame deletion of exons 2-7, resulting in constitutive EGFR activation (Felsberg et al. 2017) . Most studies of ERBB receptor family expression beyond EGFR in gliomas have used immunohistochemistry techniques (Torp et al. 2007; Duhem-Tonnelle et al. 2010; Weller et al. 2014; Felsberg et al. 2017) . ERBB1 and ERBB2 exhibit highly variable expression profiles among glioblastoma samples, whereas ERBB3 and ERBB4 are expressed at lower levels than in control (non-neoplastic cerebral cortex) tissues. However, ERBB3 may be prominently expressed in CD133-positive putative tumor stem cells (Duhem-Tonnelle et al. 2010) . Similarly, genes encoding the ERBB ligands EGF, TGF-a, HB-EGF, BTC and EREG were reported to exhibit highly heterogeneous expression profiles among glioblastoma samples and derived cell lines. NRG1, 2, 3, 4 genes were expressed at low levels relative to cerebral cortex (DuhemTonnelle et al. 2010) .
Exploiting EGFR as a therapeutic target in glioblastoma has remained challenging (Furnari et al. 2015) . Glioblastoma cell resistance to pharmacological EGFR inhibitors including antibodies, such as cetuximab or tyrosine kinase inhibitors (TKI), such as gefitinib or erlotinib has been attributed to multiple reasons. The blood-brain barrier may limit access to large molecules or hydrophilic molecules in tumor areas where the barrier is not disrupted (Lassman et al. 2005) . Primary redundance of pathway activation, or compensatory pathway activation in response to interventions, may maintain down-stream signaling even when EGFR signaling is blocked (Hegi et al. 2011) . This may involve EGFR-related family members such as ERBB2 or ERBB3 since dual inhibition of EGFR and ERBB2 with lapatinib significantly reduced glioblastoma cell proliferation compared with cetuximab (Clark et al. 2012) . ERBB2 itself has also attracted interest as a target structure for natural killer cellbased immunological treatment approaches in various cancers, including glioblastoma (Ahmed et al. 2017; Nowakowska et al. 2018) . In contrast to the antibodies, cetuximab and trastuzumab, selective siRNA-mediated gene silencing of EGFR or ERBB2 in glioblastoma cells, reduced the growth rate in vitro by 40% and 65%, respectively. EGFR gene silencing did not change migration; however, silencing of EGFR and ERBB2 reduced migration by 50% and induced radiosensitization in U251MG cells (Wichmann et al. 2015) . T98G glioma cells incubated with antisense oligonucleotides to TGF-a exhibited growth inhibition in vitro (Rubenstein et al. 2001) . Silencing of HB-EGF in U87MG cells, conditionally expressing either EGFR wildtype or EGFRvIII, attenuated EGFRvIII phosphorylation, inhibiting EGFRvIII-induced tumorigenicity, suggesting that an HB-EGF-EGFR/EGFRvIII loop regulates EGFRvIII activation (Li et al. 2014) . Inhibition of NRG1 expression by siRNA reduced the mRNA levels of L1, a cell adhesion molecule, responsible for migration of glioblastoma cells in vitro (Zhao and Schachner 2013) . Silencing of AREG, another ERBB ligand, reduced tumor growth by itself and rendered C6-4 glioma cell-derived tumors sensitive to D9-tetrahydrocannabinol treatment (Lorente et al. 2009 ). Neutralizing antibodies to EREG decreased cell proliferation in U87MG cells in vitro (Auf et al. 2013) . Altogether, these studies indicate that ERBB signaling beyond EGFR may determine the biological behavior of glioblastoma cells, notably in the setting of pharmacological interference with EGFR signaling.
Given the increasing interest in exploiting ERBB family receptors as targets for experimental therapy in brain tumors, which presently include vaccines (Weller et al. 2017b) , chimeric antigen receptor T cells (Sampson et al. 2014 ) and antibody drug conjugates (Gan et al. 2017) , the present study was conducted to provide a comprehensive characterization of ERBB family ligand and receptor expression in a large set of human glioma models, including glioma-initiating cell (GIC) models. (Lemke et al. 2014; Seystahl et al. 2015; Silginer et al. 2016 ) and cultured as spheres in neurobasal medium supplemented with 2% B27, 1% glutamine, EGF (20 ng/mL), and basic fibroblast growth factor (20 ng/mL) ( Recombinant human TGF-a (100-16A) and neuregulinb-1 (heregulinb-1) (100-03) were purchased from PeproTech (Rocky Hill, NJ, USA).
Materials and methods

Reagents and cell lines
Real-time PCR (RT-PCR)
Total mRNA extraction was performed using the NucleoSpin â RNA II system (Macherey-Nagel AG, Oensingen SO, Switzerland). 1 lg cDNA was prepared using the 'High Capacity cDNA Reverse Transcription Kit' (Applied Biosystems by Thermo Fisher Scientific, Waltham, MA, USA). Gene expression was measured by the QuantStudio TM 6 real-time PCR system and QuantStudio software V1.2 (Thermo Fisher Scientific) using PowerUpTM SYBR Green Master Mix (A25741) (Applied Biosystems by Thermo Fisher Scientific). Relative gene expression was calculated using the 2 (-delta CT) method (Livak and Schmittgen 2001) . Hypoxanthine-guanine phosphoribosyltransferase 1 (HPRT1) expression was selected for normalization. The following primers were used: hypoxanthineguanine phosphoribosyltransferase 1 (HPRT1) (forward 5 0 -TGAGG
Immunoblot analysis
Total protein extracts were prepared using radio-immunoprecipitation assay lysis buffer (pH 7.8) containing 25 mM Tris-HCl, 120 mM NaCl, 5 mM EDTA and 0.5% NP-40 supplemented with 2 lg/mL aprotinin, 10 lg/mL leupeptin, 100 lg/mL phenylmethylsulfonyl fluoride, 200 mM sodium orthovanadate, protease inhibitor cocktail (P8340) and phosphatase inhibitor cocktails 2 (P5726) and 3 (P0044) (Sigma Aldrich, St. Louis, MO, USA LTC were allowed to attach in complete DMEM for 24 h. The medium was then replaced by DMEM in the absence or presence of the corresponding agent. GIC were allowed to form spheres for 24 h in complete neurobasal medium and then supplemented with drugs at the final concentrations, as indicated. After 72 h (proliferation assay), or 8-16 days (clonogenicity), or 20 days (spherogenicity), metabolic activity was assessed by 3-(4,5-dimethylthiazolyl-2)-2,5-diphenyltetrazolium bromide (MTT), reduction.
Statistical analysis
Data reported here were derived from biological and technical replicates. Representative data of experiments, performed two to three times using triplicate wells for viability and proliferation assays and duplicate wells for RT-PCR, are shown. Quantitative data were expressed as the mean AE standard error of mean (SEM). The statistical analyses were performed by the one-way ANOVA or two-way ANOVA with Bonferroni's multiple comparison tests (GraphPad Software, La Jolla, CA, USA). Pearson's correlation coefficient was used in order to calculate correlations between mRNA and protein data. A p-value of p < 0.05 was considered statistically significant. This study was not pre-registered, does not need institutional approval, and no randomization or blinding was used.
Results
Expression and activity of EGFR in human glioma cells
We first determined EGFR mRNA expression in the cell line panel. It varied strongly among cell lines with a fold difference of 44.6 between D247MG and LN-319 among the LTC, and of 11.5 between T-269 and T-325 among the GIC models. There was no difference in expression levels between pooled LTC and pooled GIC (Fig. 1a) . Expression of the deletion variant, EGFRvIII, was not detected in any cell line, but EGFRvIII mRNA was readily detected in EGFRvIII-transfected LN-229 cells (Fan et al. 2013) which were used as a positive control (data not shown). EGFR protein was detected in all cell lines, phosphorylated EGFR (pEGFR) was also detected in all cell lines, albeit at very low levels in LN-319. Quantification of protein bands using densitometry indicated that relative to total EGFR protein levels, pEGFR levels were higher in GIC than in LTC, with a pEGFR/EGFR ratio of 1 in GIC versus 0.8 in LTC (Fig. 1b) . This is likely as a result of EGF supplementation in the GIC culture medium. The signal specificity for EGFR was confirmed by a decrease in response to the EGFR TKI gefitinib (Fig. 1c) . There was overall no correlation between EGFR mRNA, total EGFR protein and pEGFR (Table S2) , suggesting the existence of regulatory pathways of EGFR phosphorylation beyond EGFR gene expression.
Expression of ERBB receptor family members in human glioma cells Next, we determined the expression of ERBB family members in the glioma cell line panel. ERBB2 mRNA was expressed in all cell lines except ZH-161. By far the highest ERBB3 mRNA level was found in LN-229 whereas LN-428, D247MG, LN-308, S-24 and ZH-305 had low levels, and T98G was negative. ERBB4 mRNA was not detectable in the half of the cell line panel and detected at low to moderate expression levels among the other cell lines. ERBB2 protein varied considerably among cell lines whereas ERBB3 protein was detected at high levels in LN-229 cells only (Fig. 2) . ERBB4 protein was not detected in any of glioma cell lines (data not shown). mRNA and protein levels correlated for ERBB2 and ERBB3 (Table S2) . Compared with the cell line panel, The Cancer Genome Atlas (TCGA) analysis disclosed a similar relative abundance of ERBB mRNA species in human glioblastomas in vivo and revealed trend for correlation between high expression levels and inferior survival for EGFR and ERBB2, but not ERBB3 or ERBB4 ( Figure S1 ).
Expression of ERBB ligands in human glioma cells
Next, we determined the expression of ERBB family ligands in the glioma cell line panel. S-24 was the only EGF mRNA-negative cell line. At mRNA levels, EREG (in some cell lines), TGF-a and NRG1 were the dominant ligands. T98G was the only TGF-a-negative cell line. High EREG mRNA expression was detected in LN-18, U87MG and T-325 cells. BTC showed low or no expression in most of the cell lines. GIC had lower NRG1 mRNA expression than LTC, LN-308 was the only one LTC with low NRG1 mRNA. Low NRG2 mRNA expression was detected only in LN-319 and LN-308, the other cell lines showed higher mRNA levels. ZH-305 was the only NRG3 mRNA-positive cell line. ZH-161 and ZH-305 were the only AREG-positive cell lines, yet with very low expression (Fig. 3 ). There were correlations between EREG and BTC as well as between EGF and NRG1 gene expression (Table S3) . Expression of NRG1, an exclusive ERBB3 and ERBB4 ligand, correlated with ERBB1 mRNA, pEGFR in LTC and with ERBB2 mRNA. Similarly, TGF-a, an EGFR specific ligand, correlated strongly with ERBB2 protein level as well as with ERBB3 mRNA expression and protein (Table S4) . TCGA analysis showed similar relative expression levels of ERBB ligands, for example, low-level expression of AREG and NRG2-4, and revealed no major correlation between expression levels and survival (Figure S2 ).
Biological activity of EGFR signaling in maintaining the GIC phenotype Next, we analyzed glioma cell sensitivity to different anti-EGFR agents, gefitinib, a TKI of EGFR, and erbitux, a neutralizing antibody to EGFR. Neither LTC nor GIC were particularly sensitive to these agents in 72 h continuous exposure assays (Table 1 , Figure S3 ). To investigate the role of ERBB ligand family members for sphere formation, limiting dilution assays were performed in four GIC lines. Omission of EGF from the medium expectedly abrogated sphere formation in all GIC. Accordingly, gefitinib decreased spherogenicity, too. Replacement of EGF by TGF-a maintained sphere formation (Fig. 4) . In contrast, neuregulin-1 had no such effect (data not shown). Accordingly, exposure to exogenous EGF or TGF-a induced pEGFR levels strongly, whereas withdrawal of EGF or exposure to gefitinib abrogated EGFR phosphorylation (Fig. 4e) , corroborating the spherogenicity data.
Nuclear localization and subcellular regulation of ERBB receptors
It has been previously shown that EGFR can translocate from the membrane to the nucleus and may contribute to drug resistance (Li et al. 2009; Brand et al. 2011; Fan et al. 2013) . Therefore, we performed subcellular fractionation for all LTC and GIC in order to assess nuclear versus cytoplasmic fractions of phosphorylated and total EGFR. Unexpectedly, the majority of pEGFR was localized in the nuclear compartment (Fig. 5a ). Both nuclear and cytoplasmic EGFR were simultaneously decreased when ZH-161 and S-24 cells were exposed to gefitinib. Moreover, gefitinib treatment prior to EGF stimulation prevented nuclear and cytoplasmic pEGFR induction by subsequent stimulation (Fig. 5b) . Interestingly, nuclear localization was also observed for ERBB2 and ERBB3 in LN-229 cells. pERBB2, and less so pERBB3, increased in response to EGF, but only in the cytoplasmic compartment. pERBB2 was decreased by gefitinib in both fractions, although less so in the nuclear compartment, whereas cytoplasmic pERBB3 strongly increased in response to gefitinib (Fig. 5c ).
Discussion
The present comprehensive characterization of expression and biological activity of ERBB family receptors and their ligands in a large panel of glioma models was conducted because of the increasing interest in targeting these molecules for the treatment of glioblastoma. Such treatment approaches directed mainly to EGFR (ERBB1), but also to HER2 (ERBB2) include tyrosine kinase inhibitors, unarmed antibodies, antibody drug conjugates, vaccines and even cellular immunotherapies (Sampson et al. 2014; Weller et al. 2017b) , highlighting the urgent need to better understand this receptor ligand system in glioblastoma. We find that the EGFR pathway is activated as confirmed by the detection of pEGFR in almost all glioma models in vitro (Fig. 1) . This was surprising since it has previously been observed that EGFR amplification and in particular expression of the EGFRvIII deletion mutation are commonly lost upon prolonged glioma cell maintenance in culture (Bigner et al. 1990; Pandita et al. 2004) . Moreover, a certain degree of baseline EGFR activity seems to support long-term survival of glioma cells in vitro.
EGF and related ligands are present in the fetal calf serum which is used to maintain the LTC in culture over years, but pEGFR was maintained in most models even under the experimental conditions of serum-free culture used in Fig. 1 . In contrast, supplementing EGF is essential in most contemporary paradigms of maintaining GIC cultures (Lathia et al. 2015) and likely accounts for the relatively higher pEGFR levels in GIC models than in LTC models (Fig. 1) .
Beyond EGFR, cultured glioma cells also express other ERBB family members, notably ERBB2 and ERBB3, and exhibit ERBB phosphorylation, suggesting pathway activity, but in a highly cell line-specific manner (Fig. 2) . The relative expression levels allow to speculate that GIC preferentially signal via EGFR dimers or EGFR/ERBB2 heterodimers whereas the widely used LN-229 model may also signal via ERBB2/ERBB3 heterodimers since both were expressed relatively high relative to EGFR. Importantly, expression patterns in the cell line panel resembled expression data deposited in the TCGA database ( Figure S1 ), suggesting that such cell culture models may be appropriate tools to explore ERBB family molecule-directed therapies.
There was also widespread expression of EGF family ligands in the glioma cell line panel (Fig. 3) that resembled patterns of expression in the TCGA database ( Figure S2) . Some of these genes appeared to be transcriptionally coregulated (Tables S3 and S4) , indicating up-stream common regulatory pathways that might be better amenable to therapeutic intervention.
There is to date only limited data on the biological role of EGF-related growth factors in maintaining the malignant phenotype of gliomas. EGF and fibroblast growth factor are typically included in the cell culture medium used to generate patient-derived glioma cell lines directly ex vivo. In that regard, we observed that TGF-a, which acts on EGFR, but not NRG1, which only acts on ERBB3 and ERBB4, may well compensate for EGF in terms of EGFR phosphorylation and sphere formation where EGF supply is suppressed (Fig. 4) . The almost universal resistance of glioma models in vitro to clinically relevant concentrations of gefitinib or erbitux (Table 1) precluded an analysis of patterns of receptor and ligand expression associated with sensitivity or resistance to EGFR targeting.
Once activated by phosphorylation, EGFR not only induces down-stream signaling, but also enters the cytosol. Several lines of evidence indicates that a significant amount of EGFR even enters the nucleus of glioma cells to exert specific functions (Burel-Vandenbos et al. 2013; Fan et al. 2013) , for example, promoting transcription of the antiapoptotic BCL-XL gene (Latha et al. 2013) or modulating DNA repair (Dittmann et al. 2005) . It is also believed that nuclear EGFR can retain its tyrosine kinase activity and phosphorylate further substrates (Wang et al. 2006) . Our analyses confirm the accumulation of pEGFR in the nucleus (Fig. 5) . We observed that either EGF stimulation or gefitinib treatment increased or decreased cytoplasmic and nuclear pEGFR simultaneously (Fig. 5b and c) , suggesting activity of both interventions at both sites or rapid cycling or both. Importantly, besides EGFR, ERBB2 and ERBB3 may also exhibit nuclear localization. Both may contribute to evasive resistance to EGFR targeting by tyrosine kinase inhibitors since pERBB2 in the nucleus was poorly responsive to gefitinib and since pERBB3 even paradoxically increased in both compartments (Fig. 5c ). Nuclear localization of ERBB3 was previously reported in breast cancer cells (Offterdinger et al. 2002) , but these authors observed a lack of nuclear ERBB2 and absent nuclear phosphorylation of ERBB3. Sustained phosphorylation of ERBB3 can be explained by the presence of nuclear ERBB2 once pEGFR is decreased upon gefitinib treatment. Over-expression of ERBB ligands has been linked to nuclear translocation of EGFR in nonsmall cell lung cancer cells (Li et al. 2009 ) and its nuclear accumulation has been suggested to be in part responsible for intrinsic resistance to inhibitors targeting EGFR at the cell surface. Sustained nuclear pERBB2 and increased cytoplasmic phosphorylation levels of ERBB3 as observed in LN-229 cells (Fig. 5 ) warrants efforts to develop therapies targeting multiple ERBB molecules.
Despite disappointing results with EGFR TKI or EGFRvIII-directed vaccines (Furnari et al. 2015; Weller et al. 2017a) , targeting EGFR as one of the dominant molecular lesions in glioblastoma will continue to be studied, with antibody drug conjugates such as ABT-414 being the most promising approach at present (van den Bent et al. 2017; Gan et al. 2017) . Our dataset will facilitate the choice of appropriate cell culture models for future studies on ERBB family protein-directed therapies in glioblastoma. The present study suggests that a better understanding of the role of > 10 lM > 100 lg/mL A172 > 10 lM > 100 lg/mL U87MG > 10 lM > 100 lg/mL T98G > 10 lM > 100 lg/mL LN-308 > 10 lM > 100 lg/mL LN-229 6 lM > 100 lg/mL T-325 > 10 lM > 100 lg/mL T-269 10 lM > 100 lg/mL ZH-161 > 10 lM > 100 lg/mL
EC 50 values for growth inhibition were determined by MTT assay at 72 h exposure (n = 4 technical replicates). other ERBB family ligands and receptors in modulating constitutive or acquired resistance to EGFR targeting in glioblastoma will help to guide therapeutic strategies and to potentially enrich for patient populations most likely to derive benefit. Specifically, the significance of cycling of EGFR and related receptors between cellular compartments, Cells were also evaluated for the subcellular localization of phosphorylated and total epidermal growth factor receptor (EGFR) protein levels using nuclear (N) and cytoplasmic (C) fractionation (a). (b) ZH-161 or S-24 were either deprived of EGF for 24 h, or pretreated with 10 lM gefitinib for 24 h, and were then stimulated with EGF (50 ng/mL) for 15 or 60 min. (c) LN-229 cells were pretreated with gefitinib and stimulated with EGF as described in (b) and assessed for pERBB1/ERBB1, pERBB2/ERBB2 and pERBB3/ ERBB3 (n = 1). GAPDH served as loading control, lamin B1 was used as nuclear fraction loading control.
the options of co-targeting other EGFR family members together with EGFR, and the role of their adaptive upregulation in response to therapeutic interventions should receive more attention, potentially also in other EGFRaddicted cancers where treatment effects have not met expectations yet. All experiments were conducted in compliance with the ARRIVE guidelines.
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